Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cells + allogeneic dendritic cell secretome
- Development stage
- Unknown
- Lead developer
- Prodia Stem Cell Indonesia
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intramuscular
01
Overview
This experimental cell-based immunotherapy combination is being developed by PT. Prodia Stem Cell Indonesia (ProSTEM) for the treatment of advanced nasopharyngeal cancer. The therapy consists of autologous dendritic cells (derived from the patient's own immune cells) and an allogeneic dendritic cell secretome (a collection of bioactive factors and cytokines secreted by donor dendritic cells). It is intended as an adjuvant therapy for patients who have achieved a partial response or stable disease following standard radiochemotherapy. The autologous dendritic cells are designed to prime the patient's immune system against tumor antigens, while the allogeneic secretome is hypothesized to enhance the immune-stimulatory environment and inhibit cancer progression. The treatment is administered via intramuscular injection.
- Other names
- autologous dendritic cells and allogeneic dendritic cell secretomesAuto-DC and Allo-DC Secretome in Advanced Nasopharyngeal Cancer
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on autologous dendritic cells + allogeneic dendritic cell secretome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cells + allogeneic dendritic cell secretome.